311 related articles for article (PubMed ID: 25182750)
1. Impact of 11C-choline PET/CT on clinical decision making in recurrent prostate cancer: results from a retrospective two-centre trial.
Ceci F; Herrmann K; Castellucci P; Graziani T; Bluemel C; Schiavina R; Vollmer C; Droll S; Brunocilla E; Mazzarotto R; Buck AK; Fanti S
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2222-31. PubMed ID: 25182750
[TBL] [Abstract][Full Text] [Related]
2. 11C-choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT.
Ceci F; Castellucci P; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Ntreta M; Lodi F; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2014 May; 41(5):878-86. PubMed ID: 24346416
[TBL] [Abstract][Full Text] [Related]
3. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
[TBL] [Abstract][Full Text] [Related]
5. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
[TBL] [Abstract][Full Text] [Related]
6. Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
Chondrogiannis S; Marzola MC; Ferretti A; Maffione AM; Rampin L; Grassetto G; Nanni C; Colletti PM; Rubello D
Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1356-64. PubMed ID: 23670521
[TBL] [Abstract][Full Text] [Related]
7. (11)C-Choline PET/CT in patients with hormone-resistant prostate cancer showing biochemical relapse after radical prostatectomy.
Ceci F; Castellucci P; Mamede M; Schiavina R; Rubello D; Fuccio C; Ambrosini V; Boschi S; Martorana G; Fanti S
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):149-55. PubMed ID: 23151910
[TBL] [Abstract][Full Text] [Related]
8. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
11. Liver metastases from prostate cancer at 11C-Choline PET/CT: a multicenter, retrospective analysis.
Ghedini P; Bossert I; Zanoni L; Ceci F; Graziani T; Castellucci P; Ambrosini V; Massari F; Nobili E; Melotti B; Musto A; Zoboli S; Antunovic L; Kirienko M; Chiti A; Mosconi C; Ardizzoni A; Golfieri R; Fanti S; Nanni C
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):751-758. PubMed ID: 29192364
[TBL] [Abstract][Full Text] [Related]
12. Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.
Schilling D; Schlemmer HP; Wagner PH; Böttcher P; Merseburger AS; Aschoff P; Bares R; Pfannenberg C; Ganswindt U; Corvin S; Stenzl A
BJU Int; 2008 Aug; 102(4):446-51. PubMed ID: 18410442
[TBL] [Abstract][Full Text] [Related]
13. Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
Chondrogiannis S; Marzola MC; Ferretti A; Grassetto G; Maffione AM; Rampin L; Fanti S; Giammarile F; Rubello D
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1293-300. PubMed ID: 24566948
[TBL] [Abstract][Full Text] [Related]
14. Impact of total PSA, PSA doubling time and PSA velocity on detection rates of 11C-Choline positron emission tomography in recurrent prostate cancer.
Rybalov M; Breeuwsma AJ; Leliveld AM; Pruim J; Dierckx RA; de Jong IJ
World J Urol; 2013 Apr; 31(2):319-23. PubMed ID: 22814886
[TBL] [Abstract][Full Text] [Related]
15. 11C-choline PET/CT identifies osteoblastic and osteolytic lesions in patients with metastatic prostate cancer.
Ceci F; Castellucci P; Graziani T; Schiavina R; Chondrogiannis S; Bonfiglioli R; Costa S; Virgolini IJ; Rubello D; Fanti S; Colletti PM
Clin Nucl Med; 2015 May; 40(5):e265-70. PubMed ID: 25783519
[TBL] [Abstract][Full Text] [Related]
16. The role of 11C-choline PET imaging in the early detection of recurrence in surgically treated prostate cancer patients with very low PSA level <0.5 ng/mL.
Mamede M; Ceci F; Castellucci P; Schiavina R; Fuccio C; Nanni C; Brunocilla E; Fantini L; Costa S; Ferretti A; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2013 Sep; 38(9):e342-5. PubMed ID: 23797218
[TBL] [Abstract][Full Text] [Related]
17. 11C-choline PET/CT scan in patients with prostate cancer treated with intermittent ADT: a sequential PET/CT study.
Ceci F; Schiavina R; Castellucci P; Brunocilla E; Fuccio C; Colletti PM; Ferretti A; Chondrogiannis S; Rubello D; Romagnoli D; Malizia C; Martorana G; Fanti S
Clin Nucl Med; 2013 Jul; 38(7):e279-82. PubMed ID: 23698461
[TBL] [Abstract][Full Text] [Related]
18. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study.
Fuccio C; Schiavina R; Castellucci P; Rubello D; Martorana G; Celli M; Malizia C; Profitos MB; Marzola MC; Pettinato V; Fanti S
Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):1985-9. PubMed ID: 21732105
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
